Clinical significance of hypoxia in nasopharyngeal carcinoma with a focus on existing and novel hypoxia molecular imaging

Connie Yip¹², Gary J. R. Cook¹³, Joseph Wee², Kam Weng Fong², Terence Tan², Vicky Goh¹⁴

¹Department of Cancer Imaging, Division of Imaging Sciences & Biomedical Engineering, King’s College London, St Thomas’ Hospital, London SE1 7EH, UK; ²Department of Radiation Oncology, National Cancer Centre, Singapore; ³Clinical PET Imaging Centre, ⁴Department of Radiology, Guy’s and St Thomas’ NHS Foundation Trust, St Thomas’ Hospital, London SE1 7EH, UK

Contributions: (I) Conception and design: C Yip; (II) Administrative support: C Yip, V Goh, GJ Cook; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: C Yip; (V) Data analysis and interpretation: C Yip; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Dr. Connie Yip. Department of Radiology, Level 1, Lambeth Wing, St Thomas’ Hospital, Lambeth Palace Road, London SE1 7EH, UK. Email: connie.yip@kcl.ac.uk.

Abstract: Locally advanced nasopharyngeal carcinoma (NPC) is still associated with significant locoregional failure and poor overall survival (OS) after chemoradiation. The maximal therapeutic effect of conventional chemotherapy combined with radiation may have been reached and there is a clinical need to identify additional adverse prognostic factors that could be targeted therapeutically. Hypoxia, a known prognostic factor in head and neck cancers is an attractive target in NPC with various treatment strategies available such as hypoxic cell sensitisers/cytotoxins and increasing intratumoral oxygen delivery, to overcome the poorer outcomes associated with this phenotype. Thus, we aim to review the clinical significance of hypoxia as well as the current and future of molecular hypoxia imaging in NPC.

Keywords: Nasopharyngeal carcinoma (NPC); hypoxia; positron emission tomography (PET); single photon emission computed tomography (SPECT); magnetic resonance imaging (MRI)

Submitted Nov 05, 2015. Accepted for publication Dec 14, 2015.
doi: 10.21037/cco.2016.03.16
View this article at: http://dx.doi.org/10.21037/cco.2016.03.16

Introduction

Nasopharyngeal carcinoma (NPC) is uncommon with approximately 87,000 new cases which accounted for 0.6% of all cancers diagnosed worldwide in 2012 (1). The majority of cases are found in east and southeast Asia, north Africa, Middle East and the Arctic (2). NPC is a distinctive cancer that differs from other head and neck malignancies in terms of its pathogenesis, clinical progression and management strategy (3,4). It is classified into three pathological subtypes: keratinising squamous cell carcinoma (SCC), nonkeratinising carcinoma (which comprises differentiated and undifferentiated types) and basaloïd SCC (5). The Epstein-Barr virus (EBV) is implicated in the development of NPC, particularly in the endemic non-keratinising subtype with specific expression of several latent genes. These include the EBV nuclear antigen (EBNA1), latent membrane proteins (LMP1, LMP2) and EBV encoded noncoding RNAs (EBERs) in contrast to the conventional risk factors associated with head and neck SCC (HNSCC) (6,7).

Definitive (chemo)radiotherapy is the primary treatment modality in NPC with little role for surgical intervention apart from in the salvage setting. There have been few significant breakthroughs in the management of this disease since the introduction of concurrent chemoradiation in those with advanced disease which yielded 5-year overall survival (OS) rates between 67–81% and locoregional control rates of 78–90% (3). Efforts to improve these figures by means of induction chemotherapy or altered radiotherapy fractionation have been disappointing (8,9). Perhaps a more personalised and targeted approach is required to improve clinical outcomes in NPC.
Intratumoral hypoxia is an important negative prognostic factor in HNSCC (10,11). However, most if not all of these studies excluded patients with NPC and thus, the actual prevalence of hypoxia in the NPC population is still unclear. Intratumoral hypoxia is an important predictive factor for radiotherapy, and to a lesser extent, chemotherapy response (12). This could be particularly pertinent in the predominantly non-surgical management of NPC. Intratumoral oxygenation is a dynamic process which is dependent on cellular extraction or utilisation of oxygen, oxygen transport capacity, vascular perfusion and interstitial pressure (13). Conventional classification of acute hypoxia due to perfusion changes, chronic hypoxia due to increased perfusion distance in larger tumours and hypoxaemic hypoxia due to reduced oxygen transport capacity are not mutually exclusive and it is extremely difficult to clinically establish the contribution of each component to the overall tumour oxygenation status (14). The exact partial oxygen pressure (pO₂) level which defines hypoxia is dependent on the tissue or tumour type but should be the critical level that impairs normal cellular function (15). This critical pO₂ level is usually between 8 to 10 mmHg in most tumour types but the pO₂ level which causes treatment resistance could be higher and again, varies with the treatment modality involved (13). This review aims to assess the prevalence and relevance of hypoxia in NPC and to evaluate the role of non-invasive molecular hypoxia imaging in this disease.

**Evidence of hypoxia in NPC**

Overall, there is scant evidence in the published literature regarding the actual prevalence of hypoxia in NPC. The very limited pO₂ data that is available suggests that NPC tumours can be hypoxic but what proportion of nasopharyngeal tumours is indeed hypoxic is unclear. The data from pathological hypoxia assessment in NPC suggests that up to half of these tumours have some degree of hypoxia. However, whether these endogenous markers are true reflections of intratumoral oxygenation status is still debatable. In HNSCC, the proportion of hypoxic tumours can be as high as 58% and tumour oxygenation did not seem to differ between primary and nodal metastases (14,16). However, in view of the different pathogenesis and risk factors implicated in NPC, particularly the endemic form, and HNSCC which has a higher proportion of smokers and drinkers and hence, greater risk of vasculopathy, the prevalence of extreme hypoxia in NPC may be lower compared to SCC. Nonetheless, hypoxia in NPC may still be a significant problem particularly in those with bulky locoregional disease.

To date, there is no published study that examined the prevalence of intratumoral oxygenation in NPC by means of pO₂ measurement. A number of studies have evaluated the prevalence of hypoxia using polarographic needle electrode histography in head and neck cancers which included predominantly SCCs (17-25). Polarographic needle electrode histography is an automated system which uses a 250–350 μm oxygen-sensitive probe which is inserted into the tumour and progresses in a stepwise pattern over a predetermined distance, enabling multiple real-time pO₂ sampling within the tumour with fine spatial resolution (14,19). This method is considered the gold standard in intratumoral oxygenation measurement although it has several important limitations. Firstly, repeated assessment during therapy is difficult due to its invasive nature and it is not suitable for deep seated tumours. It cannot distinguish viable tumours from necrotic tissue and thus, will require additional imaging or pathological assessment for this purpose.

Other methods of tumour hypoxia assessment are quantification of downstream endogenous genomic or proteomic markers involved in hypoxia-induced cellular signalling such as hypoxia-inducible factors (HIFs), carbonic anhydrase IX (CA-IX), glucose transporter 1 (GLUT1) and osteopontin (OPN). A noteworthy study investigated the in vitro hypoxic induction of HIF-1α, HIF-2α, CA-IX and vascular endothelial growth factor (VEGF) at the mRNA and proteomic levels in four NPC cell lines representing all NPC subtypes: keratinising SCC (C666-1), undifferentiated carcinoma (C666-1) and poorly differentiated carcinoma (HONE-1, CNE-2) (26). HIF-1α expression was increased after 16 hours of hypoxia exposure in all four cell lines. Expression of CA-IX was also increased in 3 cell lines but not C666-1. However, VEGF expression was only increased after 24 hours of hypoxia exposure in C666-1, HONE1 and CNE-2 cells. HIF-2α expression was not increased in any of the cell lines following hypoxia exposure. The group also performed microarray analysis profiling hypoxic and normoxic gene expressions in HONE-1 and CNE-2 cells which showed that 4.6–7.6% of measured transcripts were regulated by hypoxia. Overall, these results suggest that the transcription and translation of hypoxic genes are probably dependent on both tumour type and duration of hypoxia exposure. OPN is a phosphoglycoprotein that is found in tumours, some normal tissues and body fluids (27). It is implicated in tumour invasion, migration and metastasis.
Research has mostly concentrated on the role of plasma OPN as a hypoxic biomarker which is thought to be shed primarily from tumour cells (28). However, this assumption should be reconsidered as plasma OPN may be derived from other tissues such as bones, immune and endothelial cells (27). In fact, OPN expression was restricted to tumour-infiltrating macrophages, not tumour cells in pancreatic adenocarcinoma (29). Whether plasma and intratumoral OPN levels can be used interchangeably as a hypoxic biomarker, if indeed it is one, could perhaps be answered by a study by Nordsmark et al. which failed to show any correlation between the blood and intratumoral OPN levels (30). In addition, OPN secretion was found to be cell line dependent and increased by reoxygenation, rather than hypoxia exposure in an in vitro study (31). These findings were supported by an in vivo study which found that intratumoral and plasma OPN levels were dependent on the strains of mice and tumour models, and OPN levels were increased by reoxygenation rather than prolonged hypoxia exposure (32). Despite the uncertainty of OPN as a true hypoxic biomarker, plasma OPN has been shown to be a significant prognostic marker in HNSCC (28,33). Although immunohistochemistry is easy to perform in clinical practice, these endogenous markers are not purely specific to hypoxia and may be affected by other biological processes in the tumour microenvironment (34). Pathological assessment is also not representative of what is happening at the whole tumour level due to sampling limitation. The cost of hypoxic genomic analysis prohibits its routine use in clinical practice at present although this may change in the future. Moreover, one cannot assume that hypoxia-induced gene expression or repression will lead to corresponding proteomic changes (35), which adds another layer of complexity in applying genomic or downstream proteomic hypoxic biomarkers to direct treatment in the clinic. In view of the potential importance of hypoxia in NPC, we will review the available evidence of hypoxia as measured using polarographic needle electrode system and pathological assessment in NPC.

A German group showed that pO₂ status in primary and nodal tumours were not significantly different in 15 HNSCC patients who had simultaneous pO₂ sampling of their primary and nodal tumours (17). The study included one patient with nasopharyngeal SCC who had nodal pO₂ sampling only. The median nodal pO₂ for this patient was 13.5 mmHg and hypoxic fraction (HF) which was defined as the percentage of pO₂ readings with values below 5.0 mmHg (HF₅₀) was 0%. Brizel et al. acquired pretreatment pO₂ measurements from 28 locally advanced HNSCC cases which included one patient with a nasopharyngeal primary (21). In contrast to the previous study, the median nodal pO₂ for this patient was 3.8 mmHg and HF₅₀ was 36%. An update of the latter study (n=63) included one additional NPC primary but no individual pO₂ data were available (22). Adam et al. measured tumour oxygenation in 37 patients with head and neck malignancies, seven of whom had received prior treatment (18). Nodal pO₂ measurement was acquired in one patient with nasopharyngeal SCC that was found to be very hypoxic: median pO₂ 1.8 mmHg, HF₂₅ 81%, HF₅₀ 94% and HF₁₀₀ 96%. Several other studies included a small number of NPC patients but did not provide individual patient data regarding the pO₂ measurements (20,23). Of interest, one of these studies evaluated the relationship between computed tomography (CT) derived tumour volume and hypoxic tumour volume as defined using pO₂ measurements (20). The latter assessment was performed mainly on nodal masses. Two out of 125 patients had nasopharyngeal SCC. The study found that CT tumour volumes positively correlated with hypoxic volumes (HV).

There are more published studies that evaluated pathological hypoxic markers in NPC (Table 1) (36-43). Most studies evaluated HIF-1α expression which was found in 32–83% of patients (Table 1). One study found that 57% of nasopharyngeal tumours expressed CA-IX (37) and VEGF expression was found in 41–80% (36,37,41,42). However, it should be noted that VEGF is not strictly a hypoxic marker, but rather an angiogenic marker whose expression is upregulated by HIF-1 (46). Patients with NPC were found to have higher levels of plasma OPN compared to normal controls (mean 185 vs. 76 ng/mL, P=0.001) but no correlation to oxygenation status was made (44). In a separate study, plasma OPN did not differ between patients with NPC and normal controls (45).

**Hypoxia as a prognostic biomarker**

To our knowledge, there is no published study which evaluated invasive pO₂ status as a prognostic marker in NPC. On the other hand, pathological hypoxic biomarkers have been studied more extensively in NPC (Table 2) (36-40, 42,47). The majority of these studies investigated HIF-1α. All but one study (36) included predominantly the undifferentiated subtype. On an individual study level, the association between HIF-1α and locoregional control, disease-free survival (DFS) and OS were rather poor with...
the 95% confidence intervals (CI) crossing the 1.00 cut-off. Furthermore, its prognostic significance was lost after adjusting for confounding factors in multivariate analyses. Nonetheless, the prognostic values of HIF-1α and HIF-2α in head and neck cancers were supported in a recent systematic review (48). A subset analysis included five studies (n=445) which looked solely at HIF-1α expression in NPC. Overexpression of HIF-1α was associated with inferior OS in all patients and also in the NPC subgroup (HR 2.07, 95% CI, 1.23–3.49). Fewer studies evaluated the prognostic role of CA-IX, VEGF and/or OPN but similar to HIF-1α, their prognostic significance was not conclusive in these retrospective studies (Table 2). Perhaps predictably, a combination of hypoxic or hypoxic and angiogenic factors appeared to provide a more robust prognostic stratification (37,42).

### Table 1 Studies that evaluated the prevalence of pathological hypoxia markers in NPC

<table>
<thead>
<tr>
<th>Study</th>
<th>No. of patients</th>
<th>Tumour subtype</th>
<th>Tumour stage</th>
<th>HIF-1α</th>
<th>CA-IX</th>
<th>VEGF</th>
<th>OPN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xueguan et al. (36)</td>
<td>59</td>
<td>Nonkeratinising carcinoma</td>
<td>II–IV</td>
<td>68%</td>
<td>—</td>
<td>49%</td>
<td>—</td>
</tr>
<tr>
<td>Hui et al. (37)</td>
<td>90</td>
<td>Nonkeratinising carcinoma</td>
<td>II–IV</td>
<td>58%</td>
<td>57%</td>
<td>60%</td>
<td>—</td>
</tr>
<tr>
<td>Kitagawa et al. (38)</td>
<td>74</td>
<td>Nonkeratinising carcinoma (n=68), keratinising SCC (n=6)</td>
<td>I–IV</td>
<td>36%</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Wan et al. (39)</td>
<td>144</td>
<td>Nonkeratinising carcinoma</td>
<td>III–IV</td>
<td>46%</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Shou et al. (40)</td>
<td>60</td>
<td>Nonkeratinising carcinoma</td>
<td>I–IV</td>
<td>70%; normal NPC epithelium: 46%</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Guang-Wu et al. (41)</td>
<td>73</td>
<td>Nonkeratinising carcinoma</td>
<td>I–IV</td>
<td>—</td>
<td>—</td>
<td>80%</td>
<td>—</td>
</tr>
<tr>
<td>Chan et al. (42)</td>
<td>78</td>
<td>Nonkeratinising carcinoma</td>
<td>II–IV</td>
<td>32%</td>
<td>—</td>
<td>41%</td>
<td>—</td>
</tr>
<tr>
<td>Benders et al. (43)</td>
<td>21</td>
<td>n/a</td>
<td>n/a</td>
<td>83%</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Wong et al. (44)</td>
<td>72+72 controls</td>
<td>Nonkeratinising carcinoma</td>
<td>I–IV</td>
<td>—</td>
<td>—</td>
<td>NPC vs. normal: mean 185 vs. 76 ng/mL</td>
<td></td>
</tr>
<tr>
<td>Hui et al. (45)</td>
<td>44+29 controls</td>
<td>Nonkeratinising carcinoma</td>
<td>I–IV</td>
<td>—</td>
<td>NPC vs. normal: mean 705 vs. 523 ng/mL (P=0.0073); HNN: mean 728 ng/mL</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

NPC, nasopharyngeal carcinoma; HIF-1α, hypoxia-inducible factor-1α; CA-IX, carbonic anhydrase IX; VEGF, vascular endothelial growth factor; OPN, osteopontin; SCC, squamous cell carcinoma; n/a, not available.

## Hypoxia imaging in NPC

Intuitively, a proportion of nasopharyngeal tumours will be hypoxic based on the extrapolation of current evidence in the HNSCC population. The degree of intratumoral hypoxia is likely to be greater with increasing tumour bulk. Besides being a potential prognostic biomarker, it would also be clinically beneficial if we could assess changes in intratumoral oxygenation during and after nonsurgical therapy, allowing us to intensify treatment, where appropriate. Both of the commonly used methods in hypoxia assessment, namely invasive pO2 sampling and immunohistochemistry are associated with limitations. An ideal hypoxic biomarker should be hypoxia-specific with selective cellular uptake at a clinically relevant pO2 level, reproducible, non-toxic and cost effective. While it is unlikely that any biomarker will fulfil all of these
Table 2 Studies that evaluated the prognostic role of hypoxia biomarker in NPC

<table>
<thead>
<tr>
<th>Study</th>
<th>No. of patients</th>
<th>Tumour subtype</th>
<th>Stage</th>
<th>Treatment</th>
<th>Prognostic markers</th>
<th>Locoregional control</th>
<th>Disease-free survival</th>
<th>Overall survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>Xueguan et al. (36)</td>
<td>59</td>
<td>Nonkeratinising carcinoma</td>
<td>II–IV</td>
<td>RT + carbogen + nicotinamide</td>
<td>HIF-1α, VEGF</td>
<td>Univariate (5-yr rates): HIF-1α (+) vs. (−): 88% vs. 95% (P=0.35); VEGF (+) vs. (−): 86% vs. 92% (P=0.32). Multivariate: n/a</td>
<td>Univariate (5-yr rates): HIF-1α (+) vs. (−): 65% vs. 90% (P=0.04); VEGF (+) vs. (−): 59% vs. 87% (P=0.01). Multivariate: HIF-1α: HR 2.48, 95% CI, 0.50–12.29 (P=0.27); VEGF: HR 3.14, 95% CI, 0.94–10.51 (P=0.06).</td>
<td>Univariate (5-yr rates): HIF-1α (+) vs. (−): 88% vs. 95% (P=0.35); VEGF (+) vs. (−): 86% vs. 92% (P=0.32). Multivariate: n/a</td>
</tr>
<tr>
<td>Hui et al. (37)</td>
<td>90</td>
<td>Nonkeratinising carcinoma</td>
<td>II–IV</td>
<td>CRT</td>
<td>HIF-1α, CA-IX, VEGF</td>
<td>Univariate: HIF-1α: RR 1.72, 95% CI, 0.87–3.39 (P=0.12); CA-IX: RR 1.28, 95% CI, 0.65–2.52 (P=0.04); VEGF: RR 1.52, 95% CI, 0.76–3.04 (P=0.24); HIF-1α + CA-IX: RR 2.06, 95% CI, 0.65–2.52 (P=0.04); VEGF: RR 1.52, 95% CI, 0.76–3.04 (P=0.24); HIF-1α + CA-IX + VEGF: RR 2.87, 95% CI, 1.25–6.59 (P=0.01). Multivariate: HIF-1α + CA-IX + VEGF: P=0.001</td>
<td>Univariate: HIF-1α: RR 2.12, 95% CI, 0.96–4.70 (P=0.06); CA-IX: RR 1.39, 95% CI, 0.64–15.63 (P=0.16)</td>
<td>Univariate: HIF-1α: RR 2.13, 95% CI, 0.95–4.80 (P=0.06); HIF-1α + CA-IX: RR 2.22, 95% CI, 0.84–5.88 (P=0.10). Multivariate: n/a</td>
</tr>
<tr>
<td>Kitagawa et al. (38)</td>
<td>74</td>
<td>Nonkeratinising carcinoma [68], keratinising SCC [6]</td>
<td>I–IV</td>
<td>CRT or RT</td>
<td>HIF-1α</td>
<td>Univariate: HIF-1α: P=0.244. Multivariate: HIF-1α: HR 1.574, 95% CI, 0.657–3.770 (P=0.309)</td>
<td>Univariate: HIF-1α: P=0.040. Multivariate: HIF-1α: HR 1.601, 95% CI, 0.918–2.790 (P=0.097)</td>
<td>Univariate: HIF-1α: P=0.026. Multivariate: HIF-1α: HR 1.290, 95% CI, 0.693–2.401 (P=0.422)</td>
</tr>
<tr>
<td>Wan et al. (39)</td>
<td>144</td>
<td>Nonkeratinising carcinoma</td>
<td>III–IV</td>
<td>CRT</td>
<td>HIF-1α</td>
<td>Univariate: HIF-1α: P=0.244. Multivariate: HIF-1α: HR 1.574, 95% CI, 0.657–3.770 (P=0.309)</td>
<td>Univariate: HIF-1α: P=0.040. Multivariate: HIF-1α: HR 1.601, 95% CI, 0.918–2.790 (P=0.097)</td>
<td>Univariate: HIF-1α: P=0.026. Multivariate: HIF-1α: HR 1.290, 95% CI, 0.693–2.401 (P=0.422)</td>
</tr>
</tbody>
</table>
### Table 2 (continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>No. of patients</th>
<th>Tumour subtype</th>
<th>Stage</th>
<th>Treatment</th>
<th>Prognostic markers</th>
<th>Locoregional control</th>
<th>Disease-free survival</th>
<th>Overall survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shou et al. (40)</td>
<td>60</td>
<td>Nonkeratinising carcinoma</td>
<td>I–IV</td>
<td>CRT or RT</td>
<td>HIF-1α</td>
<td>n/a</td>
<td>n/a</td>
<td>Univariate: HIF-1α: RR 4.192, 95% CI, 1.244–14.124 (P=0.021). Multivariate: not significant but no hazard ratios were given</td>
</tr>
<tr>
<td>Hui et al. (45)</td>
<td>31</td>
<td>Nonkeratinising carcinoma</td>
<td>I–IV</td>
<td>CRT or RT</td>
<td>OPN</td>
<td>n/a</td>
<td>n/a</td>
<td>n/a</td>
</tr>
<tr>
<td>Chan et al. (42)</td>
<td>78</td>
<td>Nonkeratinising carcinoma</td>
<td>II–IV</td>
<td>CRT or RT</td>
<td>HIF-1α, VEGF, COX-2</td>
<td>Univariate: HIF-1α + COX-2: P=0.004 (local) and P=0.007 (regional); VEGF + COX-2: P&lt;0.001 (local). Multivariate: HIF-1α + VEGF: local: HR 9.354, 95% CI, 3.019–28.14 (P&lt;0.001); regional: HR 20.72, 95% CI, 4.154–103.4 (P&lt;0.001)</td>
<td>Univariate: HIF-1α + COX-2: P=0.046. Multivariate: HIF-1α + VEGF: HR 2.922, 95% CI, 1.428–5.982 (P=0.003)</td>
<td>Univariate: No significant factors. Multivariate: no significant factors</td>
</tr>
<tr>
<td>Koukourakis et al. (47)</td>
<td>7 (+191 HNSCC)</td>
<td>Keratinising SCC</td>
<td>I–IV</td>
<td>Hyperfractionated RT or conventional RT</td>
<td>HIF-2α, CA-IX</td>
<td>Univariate (5-yr rates): HIF-2α (+) vs. (−): 42% vs. 64% (P=0.002); CA-IX (+) vs. (−): 41% vs. 65% (P=0.004)</td>
<td>n/a</td>
<td>Univariate (5-yr rates): HIF-2α (+) vs. (−): 39% vs. 61% (P=0.0004); CA-IX (+) vs. (−): 39% vs. 60% (P=0.002)</td>
</tr>
</tbody>
</table>

NPC, nasopharyngeal carcinoma; SCC, squamous cell carcinoma; HNSCC, head and neck squamous cell carcinoma; RT, radiotherapy; CRT, chemoradiation; HIF-1α, hypoxia-inducible factor-1α; CA-IX, carbonic anhydrase-IX; VEGF, vascular endothelial growth factor; OPN, osteopontin; CR, complete response; COX-2, cyclooxygenase-2; n/a, not available.
requirements, hypoxia imaging has gained considerable attention over recent years as it has the potential to fulfil most of these requirements. One of the major advantages of hypoxia imaging is its ability to acquire multiple high resolution 3-dimensional data over the regions of interest at different time points. We will review the available hypoxia imaging modalities which have been applied in NPC and novel imaging techniques that have the potential to be used in this disease. We will also discuss some relevant HNSCC studies when data on NPC is unavailable.

Positron emission tomography (PET)

Nitroimidazoles

There are several derivatives of nitroimidazole PET tracers in the clinical and research setting. In general, nitroimidazole enters the cell by passive diffusion and is reduced by nitroreductase enzymes to form RNO2 radicals. In the presence of oxygen, these radicals are rapidly reoxidised and the parent compound diffuses out of the cell. In hypoxic cells, the radical is further reduced and then binds to intracellular macromolecules, irreversibly trapping it within the cell (49). Retention of nitroimidazoles only occurs in viable cells with functional nitroreductase enzymes but not in necrotic cells (50) and is increased when pO2 falls below 10 mmHg (51). Most of the nitroimidazoles are labelled with fluorine-18 [18F] which has a physical half-life (T1/2) of 109.8 minutes (52).

[18F]Fluoromisonidazole ([18F]FMISO)

[18F]FMISO is the most extensively investigated nitroimidazole PET tracer. However, it is associated with low hypoxia-specific tissue accumulation leading to poor image contrast between hypoxic and normoxic tissues. There is slow non-hypoxic cellular washout and typically requires a 2–4 hour interval between tracer injection and image acquisition, after which the [18F] would have decayed by more than one half-life (53). Quantification of [18F] FMISO uptake has been performed using tumour-to-background ratios (TBaR) such as tumour-to-blood (TBR), tumour-to-muscle (TMR), as well as standardised uptake value (SUV), HF or HV. [18F]FMISO TBR at 2 hours post injection (TBR2h) >1.2 is generally regarded as hypoxia-specific uptake although many studies have also used the cut off of 1.4 (54). There are no definitive cut off for TMR and SUV for [18F]FMISO or any of the other nitroimidazoles.

There are many published correlative studies which attempted to examine the relationship between [18F]FMISO uptake with pO2 measurements and pathological evidence of hypoxia both in the preclinical and clinical setting (Table 3) (55–69). Despite the relatively larger number of correlative studies compared to other hypoxic radiotracers, there is an overall weak correlation between [18F]FMISO uptake and pO2 measurement (54,70). However, better correlation was observed between [18F]FMISO uptake and pimonidazole staining, an exogenous hypoxic marker, in the preclinical setting (58,59,61). Both [18F]FMISO and pimonidazole are members of the nitroimidazole family, thus have similar hypoxia retention mechanisms. Uptake probably depends on a combination of acute and chronic hypoxia as both markers have to be administered several hours prior to their evaluations compared to electrode pO2 measurement which is instantaneous, and thus may be influenced more by acute hypoxia.

An early study by Yeh et al. evaluated the use of [18F] FMISO PET to detect hypoxia in NPC (71). The study included 24 patients with NPC and 12 normal controls. A total of 370 MBq [18F]FMISO was injected intravenously and two acquisition protocols were used. The long protocol consisted of dynamic acquisition from 0 to 180 minutes and the short protocol involved two 30-minutes scan at 2 hours post injection. The authors compared TMR2h and normal nasopharynx-to-muscle ratio (NMR) in NPC patients and controls, respectively. Tumour retention of [18F]FMISO was observed after 30 minutes which persisted until 3 hours post injection. As expected, primary tumoral (mean TMR2h of 2.56±1.50) and nodal uptake (1.35±0.51) of [18F]FMISO were higher than that of normal nasopharynx (mean NMR 0.96±0.014, P<0.005). Applying a TMR2h threshold of 1.24, all primary tumours were found to be hypoxic but only 58% of cervical nodal metastases were hypoxic. Their results also suggested that there was a difference in [18F]FMISO uptake between the different tumour subtypes. Non-keratinised carcinoma (n=13) was associated with higher TMR2h compared to undifferentiated carcinoma (n=10) (3.22±1.80 vs. 1.72±0.50, P<0.05). There were too few keratinised carcinomas in this study to allow similar comparison.

[18F]FMISO PET has been evaluated as a potential prognostic biomarker as well as a treatment response and radiotherapy planning tool in HNSCC. Several studies have shown that [18F]FMISO uptake is associated with a poor prognosis in HNSCC (72-76) although others have found no such association (77,78). To our knowledge, there is only one similar study in NPC which was published as an abstract (79). This study included 40 patients who had...
Table 3: Studies which compared $[^{18}F]$FMISO uptake against pO$_2$ measurements and hypoxia immunohistochemistry

<table>
<thead>
<tr>
<th>Study</th>
<th>Study type</th>
<th>Tumour type</th>
<th>Hypoxic markers</th>
<th>PET parameters</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bentzen et al.</td>
<td>Preclinical</td>
<td>C3H mammary carcinoma</td>
<td>Polarographic pO$_2$ measurement</td>
<td>$\text{HF} = \text{ratio of radioactivity between tumour &amp; reference tissue between 225–300 minutes pi}$</td>
<td>Autoradiography showed decreased $[^{18}F]$ FMISO uptake in mice breathing Carbogen compared to normal air. No correlations between pO$_2$ measurements and $[^{18}F]$FMISO uptake</td>
</tr>
<tr>
<td>O’Donoghue et al.</td>
<td>Preclinical</td>
<td>R3327-AT anaplastic prostate adenocarcinoma</td>
<td>OxyLite fibreoptic probe which converts optical fluorescence SI to pO$_2$ values</td>
<td>FMISO images at 30 minutes to 4 hours pi</td>
<td>Spatial localisation of $[^{18}F]$FMISO uptake corresponded to areas of low pO$_2$</td>
</tr>
<tr>
<td>Chang et al.</td>
<td>Preclinical</td>
<td>R3327-AT</td>
<td>OxyLite fibreoptic probe</td>
<td>SI at 2 hours pi</td>
<td>$[^{18}F]$FMISO SI was negatively correlated with pO$_2$ ($r=-0.60$–$0.83$)</td>
</tr>
<tr>
<td>Dubois et al.</td>
<td>Preclinical</td>
<td>R1 rhabdomyosarcoma</td>
<td>Pimonidazole, CA-IX</td>
<td>$\text{HF} = \text{ratio of tumour-to-heart activity defined using thresholds ranging from 1.2–3.0 at 2 hours pi}$</td>
<td>Significant correlations observed between pimonidazole &amp; $[^{18}F]$FMISO volume ($r=0.9066$, $P=0.0001$) and CA-IX &amp; $[^{18}F]$FMISO volume ($r=0.8636$, $P=0.0006$)</td>
</tr>
<tr>
<td>Troost et al.</td>
<td>Preclinical</td>
<td>Human HNSCC (SCCNij3), human glioblastoma (E102, E106)</td>
<td>Pimonidazole</td>
<td>Autoradiography</td>
<td>Weak pixel-by-pixel correlations between pimonidazole staining &amp; mean $[^{18}F]$FMISO SI ($r^2=0.07$–$0.48$)</td>
</tr>
<tr>
<td>Troost et al.</td>
<td>Preclinical</td>
<td>Nine human HNSCC &amp; one mucoepidermoid carcinoma</td>
<td>Pimonidazole</td>
<td>Autoradiography</td>
<td>Weak pixel-by-pixel correlations between pimonidazole &amp; $[^{18}F]$FMISO images ($r=0.04$–$0.19$)</td>
</tr>
<tr>
<td>Carlin et al.</td>
<td>Preclinical</td>
<td>Human HNSCC (SQ20b) (used in all four tracer experiments), Human colon cancer (HCT116 &amp; HT29) (used only in $[^{64}Cu]$ATSM experiments), Images acquired at 80–90 minutes pi</td>
<td>Pimonidazole, CA-IX, Hoechst 33342</td>
<td>4 tracers evaluated: $[^{18}F]$ FMISO, $[^{18}F]$FAZA, $[^{6}Cu]$Hx4 &amp; $[^{64}Cu]$ATSM. Autoradiography</td>
<td>Qualitative: areas of high uptake of 2-nitroimidazoles corresponded to regions of high pimonidazole &amp; CA-IX staining, and low Hoechst 33342 staining; weak-moderate positive correlations between 2-nitroimidazole uptake and pimonidazole &amp; CA-IX staining and negative correlation with Hoechst 33342 Quantitative: weak correlations between pimonidazole &amp; 2-nitroimidazoles ($r=0.122$–$0.398$); weak-moderate correlations between CA-IX &amp; 2-nitroimidazoles ($r=0.140$–$0.433$); weak-moderate correlations between Hoechst 33342 &amp; 2-nitroimidazoles ($r=0.004$–$0.424$)</td>
</tr>
<tr>
<td>Hueting et al.</td>
<td>Preclinical</td>
<td>EMT6 mouse mammary cell line, CaNT murine adenocarcinoma</td>
<td>EF5</td>
<td>Autoradiography</td>
<td>Good correlation between $[^{18}F]$FMISO uptake &amp; EF5 ($r&gt;0.8$)</td>
</tr>
</tbody>
</table>

Table 3 (continued)
<table>
<thead>
<tr>
<th>Study</th>
<th>Study type</th>
<th>Tumour type</th>
<th>Hypoxic markers</th>
<th>PET parameters</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zimny et al.</td>
<td>Clinical</td>
<td>HNSCC (n=22), Hodgkin's lymphoma (n=1), lymphoepithelial cancer (n=1)</td>
<td>Polarographic pO\textsubscript{2} measurement</td>
<td>TMR\textsubscript{2hr} &amp; TBR\textsubscript{2hr}</td>
<td>Moderate correlations between pO\textsubscript{2} HF ≤2.5 (r=0.50/5.0 mmHg r=0.54) and \textsuperscript{[18]F}FMISO TMR. Correlations were improved after exclusion of 2 outliers with mainly necrotic tumours (r=0.78–0.80)</td>
</tr>
<tr>
<td>Gagel et al.</td>
<td>Clinical</td>
<td>HNSCC (n=20)</td>
<td>Polarographic pO\textsubscript{2} measurement</td>
<td>TMR\textsubscript{2hr} &amp; TBR\textsubscript{2hr}</td>
<td>Good correlations between pO\textsubscript{2} HF (r=0.703–0.757), &amp; median (r=−0.589) and mean pO\textsubscript{2} (r=−0.582) with \textsuperscript{[18]F}FMISO TMR. Weaker correlations between pO\textsubscript{2} HF (r=0.435–0.478), median (r=−0.278) and mean pO\textsubscript{2} (r=−0.272) with \textsuperscript{[18]F}FMISO TBR</td>
</tr>
<tr>
<td>Mortensen et al.</td>
<td>Clinical</td>
<td>HNSCC (n=9), soft-tissue sarcoma (n=5), benign soft tissue tumours (n=4)</td>
<td>Polarographic pO\textsubscript{2} measurement</td>
<td>TMR at 150–249 minutes pi</td>
<td>No significant correlation between pO\textsubscript{2} measurements and \textsuperscript{[18]F}FMISO uptake</td>
</tr>
<tr>
<td>Cherk et al.</td>
<td>Clinical</td>
<td>NSCLC (n=17)</td>
<td>HIF-1\textalpha, GLUT1</td>
<td>SUV\textsubscript{max} at 2 hours pi</td>
<td>No significant correlations between SUV\textsubscript{max} &amp; HIF-1\textalpha/GLUT1 expressions</td>
</tr>
<tr>
<td>Norikane et al.</td>
<td>Clinical</td>
<td>Head &amp; neck (n=24) including 2 NPC</td>
<td>HIF-1\textalpha</td>
<td>TBR\textsubscript{2hr}</td>
<td>Weak correlation between HF &amp; HIF-1\textalpha staining (r=0.40). No correlation between TBR &amp; HIF-1\textalpha staining (r=0.09)</td>
</tr>
<tr>
<td>Sato et al.</td>
<td>Clinical</td>
<td>HNSCC (n=23)</td>
<td>HIF-1\textalpha</td>
<td>SUV\textsubscript{max} at 4 hours pi</td>
<td>No significant correlation between SUV\textsubscript{max} &amp; HIF-1\textalpha expression</td>
</tr>
<tr>
<td>Kawai et al.</td>
<td>Clinical</td>
<td>High grade gliomas (n=48)</td>
<td>HIF-1\textalpha</td>
<td>TBR\textsubscript{2hr}</td>
<td>No significant correlation between TBR &amp; HIF-1\textalpha expression</td>
</tr>
</tbody>
</table>

HF, hypoxic fraction; pi, post injection; SI, signal intensity; HNSCC, head and neck squamous cell carcinoma; TMR, tumour-to-muscle ratio; TBR, tumour-to-blood ratio; SUV, standardised uptake value; HIF-1\textalpha, hypoxia-inducible factor-1\textalpha; CA-IX, carbonic anhydrase-IX; GLUT1, glucose transporter 1; NSCLC, non-small cell lung cancer.
pretreatment $[^{18}F]$FMISO and $[^{18}F]$FDG PET. Patients were injected with 370 MBq of $[^{18}F]$FMISO and PET was acquired at 2 hours post injection. Hypoxia was defined as $[^{18}F]$FMISO TMR$_{4hr} > 1.24$. Overall, 75% of all patients had baseline PET-defined hypoxia. Fewer number of complete responders (n=25) had baseline hypoxia compared to non-responders or those with disease relapse (64% vs. 93%).

In contrast, there are more studies which utilised $[^{18}F]$FMISO PET in NPC radiotherapy planning. A Korean group performed a dose escalation radiotherapy planning study in a small cohort of head and neck malignancies (80). Six out of eight patients had locally advanced NPC. Static PET image acquisition was performed at 2 and 4 hours post intravenous injection of approximately 740 MBq of $[^{18}F]$FMISO. Interestingly, the group used tumour-to-cerebellum ratio (TCR) $\geq 1.3$ to define hypoxic gross tumour volume (GTV$_h$) instead of TMR which they postulated could be affected by cervical muscle strain secondary to anxiety or stress. A 3 mm margin was applied to GTV$_h$ to generate hypoxic planning target volume (PTV$_h$). Dose escalation to the GTV$_h$ from the standard 72 to 84 Gy delivered over 30 fractions was simulated using simultaneous-integrated boost intensity-modulated radiotherapy (SIB IMRT). Mean intratumoral $[^{18}F]$FMISO SUV maximum (SUV$_{max}$) was found to be 2.1±0.9 and the mean GTV$_h$-to-standard GTV ratio was 16.3%±24.7%. Dose escalation was not feasible in two NPC patients with T4N2 disease due to brainstem and spinal cord tolerance, respectively. Dose escalation of up to 78–84 Gy was feasible in the other patients.

A Japanese group investigated the radiotherapy planning and prognostic roles of $[^{18}F]$FMISO acquired on a new PET/CT scanner using lutetium oxyorthosilicate scintillation detectors and extended field of view which provided better image contrast, with images acquired on a conventional PET/CT scanner with bismuth germanium oxide scintillation detectors in 16 patients with NPC (81). The patients were injected with 400 MBq of $[^{18}F]$FMISO and images were acquired at 4 hours post injection. Hypoxia was defined as TMR$_{4hr}$ greater than the average nasopharynx-to-muscle uptake in normal controls +1.96 standard deviation. Overall, 13/16 (81%) patients had increased $[^{18}F]$FMISO uptake: mean TMR$_{4hr}$ 1.35 (new PET) and 1.23 (conventional PET/CT). IMRT dose escalation planning simulations using both the new and conventional $[^{18}F]$FMISO PET images were performed in ten patients to deliver 84 Gy to the GTV$_h$. No GTV$_h$ margin expansion was applied to generate PTV$_h$. The GTV$_h$ derived from the new PET was smaller (1.5±1.6 cc) compared to that derived from conventional PET/CT (4.7±4.6 cc, P=0.002), which the authors attributed to variation in scatter fraction and spatial resolution. Superior dose distribution was achieved using the new PET data. Dose escalation was feasible in all new PET-guided plans in contrast to 9 out of 10 conventional PET plans. In comparison to the previous study by Choi et al., there was a lower proportion of patients with T4 disease in this study, which may account for the difference in the number of successful dose escalations. Perhaps a more pertinent point to consider prior to the clinical implementation of any hypoxia imaging-guided dose escalation is that the GTV$_h$ volumes can vary as much as 31% solely due to the use of different scanners as demonstrated in this study. Besides that, the inherent temporal variation of any hypoxia biomarker uptake has to be taken into account as a radiotherapy plan is generated based on a set of images acquired at one time point, with a real risk of missing the hypoxic target volume over a typical fractionated treatment time of 6–7 weeks. This is supported by a $[^{18}F]$FMISO PET/CT reproducibility study by Nehmeh et al. that included 14 patients with HNSCC (82). Pretreatment $[^{18}F]$fluorodeoxyglucose (FDG)-PET/CT was performed for radiotherapy planning. Two sequential pretreatment $[^{18}F]$FMISO PET/CT scans were performed 3 days apart. Images were acquired at an average of 162 minutes post injection of 385 MBq $[^{18}F]$FMISO for both scans. Voxel-by-voxel image registration was performed using the CT datasets. HVs were defined using the TBR threshold of 1.2. Although relatively good correlation between the two scans was found when all voxels within the $[^{18}F]$FDG-derived tumour volumes were considered (average r=0.6), the correlation was much poorer when the analysis was limited to voxels with TBR $\geq 1.2$ (r=0.3) due to the contribution of lower intensity voxels in the former analysis. The lack of stability of intratumoral high-intensity $[^{18}F]$FMISO distribution is a critical issue in fractionated radiotherapy treatment which may in contrast to the general belief, compromise tumour control. Hence, any biological radiotherapy dose painting treatment should be performed within the context of a prospective study to evaluate the long-term tumour control and safety data of each imaging biomarker using standardised image acquisition hardware and software before we can fully embrace it in clinical practice.

To our knowledge, there is no published data regarding treatment-induced changes in $[^{18}F]$FMISO PET in
NPC. Temporal changes of $[^{18}\text{F}]$FMISO uptake during chemoradiation and chemotherapy in HNSCC have been assessed but no firm conclusions about the significance of these results can be made due to the small sample size in these studies (73,78).

$[^{18}\text{F}]$Fluoroazomycin arabinofuranoside ([$^{18}\text{F}]$FAZA)

$[^{18}\text{F}]$FAZA is one of the second generation nitroimidazoles which is coupled to an arabinose sugar thus increasing its lipophilicity and subsequent clearance from non-hypoxic tissues (83). This should improve tumour-to-background uptake ratios although intratumoral accumulation of $[^{18}\text{F}]$FAZA was shown to be less than that of $[^{18}\text{F}]$FMISO (61). Nonetheless, another preclinical study showed that $[^{18}\text{F}]$FAZA was associated with higher TBR and TMR compared to $[^{18}\text{F}]$FMISO (84). $[^{18}\text{F}]$FAZA TBR was shown to be maximal and stable at 2 hours post injection (85).

A few preclinical studies compared $[^{18}\text{F}]$FAZA uptake with endogenous and exogenous hypoxic markers in SCC and fibrosarcoma xenografts (86-88). Overall, there were significant positive correlations observed between spatial localisation of $[^{18}\text{F}]$FAZA and pimonidazole (86,87). The same group also used a different method to quantify the correlation between $[^{18}\text{F}]$FAZA and hypoxia mRNA biomarkers such as GLUT1, CA-IX and lysyl oxidase (LOX) by analysing the respective uptake and transcription by weight in fragmented tissues (88). They found a strong correlation between $[^{18}\text{F}]$FAZA retention and hypoxia gene expression profile. Another group compared $[^{18}\text{F}]$FAZA uptake with $p_O2$ estimation using the OxyLite fibroptic system which converts optical fluorescence signal intensities to $p_O2$ values in a rhabdomyosarcoma xenograft model (89). The group used TBA-R at 3 hours post injection, whereby background was defined as a volume within the pelvic region. The group found that $[^{18}\text{F}]$FAZA TBA-R was lower and $p_O2$ was higher in the carbogen-breathing animals compared to those breathing room air. However, the correlation between the two parameters was only moderate at best ($r=0.50$–0.55).

There are no published studies which evaluated $[^{18}\text{F}]$FAZA PET in NPC alone. The DAHANCA group evaluated the prognostic value of $[^{18}\text{F}]$FAZA PET in 40 patients with HNSCC which included 3 patients with nasopharyngeal primary (90). All patients were treated with concurrent chemoradiation and the hypoxic cell sensitiser, nimorazole. All patients underwent pretreatment $[^{18}\text{F}]$FAZA PET/CT and 13 had a second PET/CT which was performed during treatment. For the scan, an average of 365 MBq $[^{18}\text{F}]$FAZA was injected intravenously and a static PET acquisition was undertaken at 2 hours post injection. Twenty-five (63%) patients had evidence of tumour hypoxia which was defined as TMR $\geq 1.4$. $[^{18}\text{F}]$FAZA uptake was associated with inferior DFS (60% vs. 93%, $P=0.04$). Seven out of 13 patients who underwent a second PET scan showed no evidence of residual $[^{18}\text{F}]$FAZA uptake. The other six patients had smaller HVs within the same region as the initial PET scan, suggesting reoxygenation occurred during treatment.

Souvatzoglou et al. performed a pilot study comparing dynamic and static $[^{18}\text{F}]$FAZA PET acquisition in 11 head and neck patients including one patient with NPC (91). Dynamic acquisition was performed up to 4 hours following a 315 MBq injection of $[^{18}\text{F}]$FAZA. In addition, static PET was acquired at 2 and 4 hours post injection. The authors found that static $[^{18}\text{F}]$FAZA imaging at 2 hours post injection provided the optimal signal-to-background ratio. The same group expanded the study (n=18) and showed that it was feasible to escalate the radiation dose to 80.5 Gy to the $[^{18}\text{F}]$FAZA-defined GTV$_{in}$, which included all voxels with $[^{18}\text{F}]$FAZA uptake $\geq 50\%$ of background muscle SUV$_{mean}$ (92).

A Dutch group performed four sequential $[^{18}\text{F}]$FAZA PET/CT scans in six patients with stage IV head and neck cancers (93). Patients were imaged at baseline, week 1, week 2 and week 4 of chemoradiation. Fractional HV (FHV) was defined as the volume within the FDG-derived GTV with $[^{18}\text{F}]$FAZA TMR $\geq 1.4$. They found that 5 out of 6 patients had significant baseline intratumoral hypoxia (FHV $>10\%$). FHV decreased during the course of treatment but remained relatively stable after week 2. The authors concluded that $[^{18}\text{F}]$FAZA PET/CT at week 2 rather than at baseline may be the most reliable for dose escalation radiotherapy planning.

Other nitroimidazoles

Various second generation nitroimidazoles with improved pharmacokinetics and clearance properties compared to $[^{18}\text{F}]$FMISO have been evaluated in head and neck cancers although their evidence in NPC is lacking. $[^{18}\text{F}]$Fluoroerythronitroimidazole ($[^{18}\text{F}]$FETNIM) is a hydrophilic nitroimidazole which has been studied in HNSCC (94-96). $[^{18}\text{F}]$FETNIM tumour-to-mediastinum ratio was shown to have moderate correlations with GLUT1, HIF-1$\alpha$ and VEGF staining in non-small cell lung cancer (NSCLC) (97). The Turku group has the most experience with $[^{18}\text{F}]$FETNIM PET/CT in head and neck cancers (98).
cancers and they suggested that the initial $^{[18]}$F-FETNIM uptake is influenced by blood flow and hypoxia-specific signal is optimal at 60–90 minutes post tracer injection (94). The group further evaluated this association in a cohort of patients with HNSCC including two nasopharyngeal primaries (96). $^{15}$O-labelled water ($[15]$O$\text{H}_2$O) PET was used as a surrogate for tumour blood flow. Following completion of $^{[15]}$O$\text{H}_2$O PET, between 289–385 MBq of $^{[18]}$F-FETNIM was injected intravenously. Two image acquisition protocols were used: dynamic for 120 minutes post injection and static acquisitions at 0–20 and 80–120 minutes. $^{[18]}$F-FETNIM quantification was calculated using the data acquired between 90–120 minutes. Hypoxia was defined as tumour-to-plasma activity more than three standard deviations above the average normal tissue-to-plasma activity ratio which was based on this particular cohort of patients. In this study, blood flow was not associated with $^{[18]}$F-FETNIM FHV or tumour-to-plasma ratio. The two NPC primaries exhibited moderate intratumoral blood flow (20 and 37 mL/100 g/min) with corresponding HFV of 20% and 34%. The study found that FHV greater than the median was associated with inferior OS ($P=0.036$).

The study also evaluated the association between the uptake of the tracers and CA-IX staining in nine patients. Both tracers showed good association with CA-IX expression.

**Cu-ATSM**

Cu-ATSM is a lipophilic Cu(II) complex that rapidly passes through the cell membrane. Its exact retention mechanism within hypoxic cells is still unclear (102,103). All hypotheses involve the reduction of Cu(II) to Cu(I) with various intracellular reducing agents being proposed such as mitochondrial nicotinamide adenine dinucleotide (NADH) (102) and cytoplasmic reductants such as NADPH (103). It is thought that Cu-ATSM is reduced in both normoxic and hypoxic cells to the less lipophilic and unstable Cu(I)-ATSM complex. This process is reversible in the presence of oxygen, allowing the reoxidised Cu-ATSM to diffuse out of the cell. However, this is irreversible in the hypoxic environment, thus trapping the Cu(I) ions within hypoxic cells (104-106). A number of copper isotopes with varying physical half-lives can be used to label this compound: $^{60}$Cu ($T_{1/2} = 24$ minutes), $^{61}$Cu ($T_{1/2} = 3.3$ hours), $^{62}$Cu ($T_{1/2} = 9.7$ minutes) and $^{64}$Cu ($T_{1/2} = 12.7$ hours) (49). Due to very short half-life of $^{62}$Cu, it has to be produced on-site in a $^{62}$Zn/$^{62}$Cu generator (107). The choice of isotopes will depend on studied hypothesis and availability of isotopes.

The specificity of Cu-ATSM as a true hypoxia biomarker is still being debated. Table 4 shows the studies which have evaluated the evidence in this aspect (56,61,62,108-110). The hypoxia selectivity of Cu-ATSM has been suggested to be cell line (108,111) and time dependent (56,62). This is supported by the finding that fatty acid synthase expression, a marker of tumour aggressiveness in prostate cancer, inhibited $^{64}$Cu-ATSM retention in several prostate carcinoma cell lines (112). The conflicting evidence for its hypoxia selectivity may be partly attributed to all these reasons, leading to opinions that Cu-ATSM retention may not be entirely hypoxia specific but dictated by the intracellular redox potential (62,113). Despite this, Cu-ATSM uptake has been shown to be a significant prognostic factor in NSCLC, cervical and rectal cancers which could be independent of its status as a true hypoxic biomarker (114-116).

The role of Cu-ATSM PET in head and neck cancers has been studied but no published study has evaluated its
<table>
<thead>
<tr>
<th>Study</th>
<th>Study type</th>
<th>Radiotracer</th>
<th>Tumour type</th>
<th>PET parameters</th>
<th>Hypoxic markers</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carlin et al. (61)</td>
<td>Preclinical</td>
<td>$^{64}$CuATSM. Images acquired at 80–90 minutes pi</td>
<td>Human HNSCC (SQ20b) (used in all four tracer experiments), Human colon cancer (HCT116 &amp; HT29) (used only in $^{64}$CuATSM experiments)</td>
<td>4 tracers evaluated: $^{18}$F]FMISO, $^{18}$F]FAZA, $^{18}$F]HX4 &amp; $^{64}$CuATSM. Autoradiography</td>
<td>Pimonidazole, CA-IX, Hoechst 33342</td>
<td>Quantitative: areas of high uptake of $^{64}$CuATSM corresponded to regions of low Pimonidazole &amp; CA-IX staining, and high Hoechst 33342 staining. Qualitative: negative weak correlations between $^{64}$CuATSM and pimonidazole ($r=-0.110$) &amp; CA-IX ($r=-0.158$) but positive correlation with Hoechst 33342 ($r=0.077$)</td>
</tr>
<tr>
<td>Yuan et al. (108)</td>
<td>Preclinical</td>
<td>$^{64}$CuATSM. Dynamic acquisition for 1 hour pi</td>
<td>R3230 mammary adenocarcinoma, fibrosarcoma (FSA), 9L gliosarcoma</td>
<td>Autoradiography</td>
<td>EF5, pimonidazole, CA-IX, Hoechst 33342</td>
<td>Cell line dependency of $^{64}$CuATSM hypoxia selectivity: significant $^{64}$CuATSM uptake &amp; EF5 staining correlations observed in R3230 ($r=0.74\pm0.02$) and 9L ($r=0.61\pm0.04$) tumours but not FSA ($r=0.11\pm0.03$); no spatial correlation between pimonidazole &amp; CA-IX with $^{64}$CuATSM autoradiography in FSA tumours but good spatial correlation observed in R3230. Carbogen effect in FSA xenograft: EF5 staining decreased in Carbogen-breathing animals compared to air-breathing animals but no significant decrease in $^{64}$CuATSM uptake</td>
</tr>
<tr>
<td>O’Donoghue et al. (56)</td>
<td>Preclinical</td>
<td>$^{64}$CuATSM. Early acquisition: 30 min–2 hours pi and late: 16–20 hours pi</td>
<td>R3327-AT anaplastic prostate adenocarcinoma</td>
<td>Autoradiography</td>
<td>OxyLite fibreoptic probe which converts optical fluorescence SI to pO$_2$ values. Pimonidazole, Hoechst 33342</td>
<td>Late $^{64}$CuATSM images corresponded better to pO$_2$ measurements compared to early images. Negative correlations observed between early $^{64}$CuATSM uptake &amp; pimonidazole ($r=-0.76/0.77$) and equivocal correlations with Hoechst 33342 ($r=0.34/0.36$). Positive correlations observed between late $^{64}$CuATSM uptake &amp; pimonidazole ($r=0.61/0.64$) and equivocal correlations with Hoechst 33342 ($r=0.35/0.11$)</td>
</tr>
</tbody>
</table>

Table 4 (continued)
use in NPC (Figure 1). A Japanese pilot study showed that a pretreatment $^{62}$CuATSM SUV$_{max}$ > 5.0 was associated with inferior locoregional control following chemoradiation in 17 patients with advanced head and neck cancers (117). In a separate study, $^{62}$CuATSM TMR > 3.2 predicted for inferior DFS and progression-free survival (PFS) in 22 patients with head and neck malignancies (118). However, $^{62}$CuATSM SUV$_{max}$ > 3.6 was associated with poorer PFS but not DFS in the same study. Grassi et al. assessed the prognostic role of early (1 hour post injection) and late $^{64}$CuATSM PET/CT (16 hours post injection) in eleven patients with advanced head and neck malignancies, of whom one had nasopharyngeal cancer (119). No significant difference was found between early and late PET acquisitions. A $^{64}$CuATSM SUV$_{max}$ threshold of 17.8 was associated with good sensitivity (100%) but poor specificity (50%) in predicting complete response after chemoradiation with an area under the curve (AUC) of 0.7. It has to be noted that these studies included a small heterogeneous population and these results should be validated in larger studies.

Cu-ATSM guided head and neck radiotherapy planning was first considered by Chao et al. using $^{60}$CuATSM PET/CT (120). The group used $^{64}$CuATSM TMR > 2.0 to define hypoxia in this study. The GTV$_h$ was simulated to receive 80 Gy in 35 fractions without compromising normal tissue tolerances. The stability of hypoxia within head and neck tumours as depicted on Cu-ATSM PET during treatment was assessed by Nyflot et al. in a phase I therapeutic study evaluating the addition of bevacizumab to concurrent chemoradiation (121). All ten patients had stage IV oropharyngeal SCC and received induction bevacizumab followed by concurrent chemoradiation 3 weeks later. Patients underwent $^{18}$F fluorothymidine (FLT) imaging, a marker of cellular proliferation, and $^{64}$CuATSM PET/CT at three time points: before treatment, 3 weeks after induction bevacizumab and during week 1–2 of chemoradiation. All patients showed significant reductions in $^{18}$F FLT SUV$_{mean}$ and SUV$_{peak}$ after induction bevacizumab and chemoradiation. In contrast, although there was a significant overall reduction in $^{64}$CuATSM SUV$_{mean}$ during treatment, these changes were less consistent in an individual patient basis which was similar to the preclinical findings of the heterogeneous Cu-ATSM uptake between different cell lines and xenografts.

Overall, there is very little evidence on the use of Cu-ATSM in NPC but the limited data in the head and neck cancer cohort suggests that there is potential for its use as a prognostic biomarker. Its use in radiotherapy planning
Figure 1 $^{64}$CuATSM PET/CT (left) and corresponding $^{18}$FFDG PET/CT (right) of an (A) oropharyngeal primary with ipsilateral cervical lymphadenopathy showing increased FDG uptake but only mild $^{64}$CuATSM uptake in the primary tumour and (B) enlarged FDG-avid right cervical lymph node with increased $^{64}$CuATSM at the periphery. Used with permission from Dr. Suh Yae-Eun and Dr. Teresa Guerrero-Urbano, Department of Clinical Oncology, Guy's & St Thomas' NHS Foundation Trust, London, UK. PET, positron emission tomography; CT, computed tomography.

is feasible but we are faced with the same difficulty as with the nitroimidazoles with regards to temporal variation in intratumoral oxygenation. In addition, the uncertainty of Cu-ATSM as a true hypoxia biomarker should ideally be resolved before it is used to direct hypoxia-targeting therapy.

**Single photon emission computed tomography (SPECT)**

SPECT hypoxia imaging is feasible although research into its use in the aspect has received less attention than PET in recent years. SPECT radiotracers typically have longer half-lives compared to PET tracers, permitting delayed imaging
to be performed. The spatial resolution and detection sensitivity of SPECT are lower than PET but a SPECT scanner is cheaper compared to PET which could be an important factor in terms of cost-effectiveness in certain healthcare systems (122). Quantification of SPECT tracer uptake is also less developed compared to PET.

**Iodoazomycin arabinoside (IAZA)**

IAZA is a misonidazole analogue which has been proposed as a hypoxia imaging biomarker and can be coupled to iodine-123 ($^{123}$I) ($T_{1/2} = 13$ hours) or $^{125}$I ($T_{1/2} = 59$ days) (123). *In vitro* study showed high $^{123}$I avidity in hypoxic EMT6 cells whereas little $^{123}$I IAZA uptake occurred in oxic cells (124). Parliament et al. demonstrated adequate $^{123}$I IAZA uptake at 18–24 hours post injection in predominantly lung cancers (125). The same group went on to compare $^{123}$I IAZA and $^{99m}$Tc hexamethylpropylenamine oxime ($^{99m}$Tc HMPAO) SPECT, a surrogate of perfusion in a separate study (n=22) which included six head and neck patients (126). They found an inverse correlation between $^{123}$I IAZA and $^{99m}$Tc HMPAO uptakes, mainly of poorly perfused areas that corresponded to areas with increased $^{123}$I IAZA uptake. An expanded study cohort of 52 patients which included those with head and neck cancers (n=6), small cell lung cancer (n=15), malignant gliomas (n=11) and other malignancies showed that 40% of the head and neck tumours were hypoxic, defined as TBR >1.10 (127). A similar inverse relationship between $^{123}$I IAZA and $^{99m}$Tc HMPAO uptakes was shown except in the glioma subgroup in which none of the patients showed uptake of $^{123}$I IAZA. This could perhaps be attributed to the presence of significant intratumoral necrosis, a common phenomenon in glioblastoma, although this information was not given to confirm this hypothesis.

**HL91**

$^{99m}$Tc Butylene amineoxime ($^{99m}$TcHL91) is a single-photon-emitting radiotracer without the 2-nitroimidazole group and has greater hypoxia selectivity compared to the 2-nitroimidazole-containing tracers (128). The uptake of $^{99m}$TcHL91 was shown to correlate with GLUT1 expression in rat mammary carcinoma xenografts (129). A small study evaluated the potential of $^{99m}$TcHL91 SPECT in detecting locoregional recurrence in head and neck cancers (130). Nine patients with suspicious clinical recurrence were recruited and underwent conventional CT and $^{99m}$TcHL91 SPECT. SPECT acquisition was performed at 2 and 4 hours post injection of tracer. Five patients were subsequently confirmed to have local recurrence on CT and biopsy. $^{99m}$TcHL91 SPECT detected 3 local recurrences and 2 out of 3 nodal recurrences. The study did not find any significant difference between early and late $^{99m}$TcHL91 tumour-to-normal tissue ratios. Based on this limited evidence, $^{99m}$TcHL91 SPECT is unlikely to be used as a first-line imaging tool in detecting *de novo* or recurrent tumours.

**Future directions**

Molecular hypoxia imaging assessment in NPC is limited but we can probably extrapolate some data from the HNSCC population. There is perhaps less doubt about the significance of hypoxia as a negative prognostic and predictive factor in NPC than the actual prevalence of clinically and radiobiologically relevant hypoxia in this disease. Hence, more research should be done to ascertain the prevalence of hypoxia in NPC. A true hypoxia imaging biomarker which is not affected by tumour perfusion and blood flow, amongst other criteria as discussed before, will be the ideal clinical tool to use but such a biomarker is unlikely to exist.

The future of hypoxia assessment is likely to involve multimodality functional imaging. Simultaneous assessment of hypoxia and perfusion/blood flow will be desirable, allowing oncologists to target the predominant process contributing to hypoxia. The combined use of different functional imaging modalities such as PET, magnetic resonance imaging (MRI) and CT should be considered. CT and MRI have advanced beyond conventional anatomical imaging. Functional MRI such as blood oxygen dependent (BOLD), dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) MRI can provide additional evaluation of tumour oxygenation, perfusion/blood flow and cellular density, respectively. BOLD MRI is based on the intrinsic differential magnetic properties of oxyhaemoglobin and deoxyhaemoglobin. The paramagnetic deoxyhaemoglobin shortens the T2* of blood and increases the MR transverse relaxation rate (R2* = 1/T2*) measured using gradient echo (GRE) sequences (131). DCE-MRI evaluates the tumour enhancement characteristics before and after a fast bolus of intravenous low-molecular weight gadolinium contrast agent injection using T1-weighted spoiled GRE sequence (132). The use of DCE-MRI has been recently been evaluated in NPC with encouraging...
results (133-135). DW MRI measures the rate of water Brownian motion within tissues using a pair of field gradients with varying amplitudes and gradient durations which are both summarised as \( b \)-values, that defocus and refocus signals of water molecules (136). Quantitative assessment is possible by acquiring images using at least two \( b \)-values to generate apparent diffusion coefficient (ADC) which is an average of water motion in three directions. Hypercellular tumours exhibit restricted diffusion and corresponding low ADC. Although often thought as measurement of tissue diffusivity, the DW signal attenuation is affected by both molecular diffusion and microcirculation of blood in the capillary network (137,138). Intravoxel incoherent motion (IVIM)-based analysis permits estimation of tumour perfusion and diffusivity by performing DW MRI using multiple \( b \)-values (usually more than 10). The measured signal attenuation acquired using low \( b \)-values is affected predominantly by microcapillary perfusion whereas signal attenuation at higher \( b \)-values is less sensitive to perfusion. IVIM-based analysis has been investigated in NPC to differentiate malignant tumours from radiation fibrosis (139) and benign tumours (140), to predict locoregional tumour staging (141) and response to neoadjuvant chemotherapy (142). Although initial results are promising, there are significant challenges to overcome before we can introduce this technique into clinical practice. Measurements of signal attenuation at low \( b \)-values are susceptible to signal-to-noise variations and have poor reproducibility. In addition, the optimal mathematical model to quantify perfusion and diffusion characteristics is still unclear (138). Similar to DCE-MRI, perfusion CT assesses the temporal changes in tumour attenuation after intravenous iodinated contrast administration, allowing estimation of intratumoral blood flow, blood volume and vessel permeability (143,144). Although sequential PET and functional MRI/CT can be performed on different occasions, near simultaneous acquisitions of PET and MRI/CT will be advantageous in terms of patient convenience and minimising the effect of temporal heterogeneity between scans. The introduction of PET/MRI has the potential to improve diagnostic and radiotherapy planning ability although there is still much uncertainty regarding the use of MR attenuation correction and research is still on going in this area. Nonetheless, this is an exciting prospect in hypoxia imaging particularly in NPC where the superior soft tissue definition on MRI will be clinically valuable.

Contrast-enhanced ultrasonography using microbubbles of injectable gas in a shell made up of phospholipids, proteins or polymer that remain intravascularly can be used to assess tumour perfusion (145). These microbubbles of 1–4 μm in diameter are safe for patient use. The feasibility of this method to assess perfusion in liver and nodal metastases as well as renal cell carcinoma has been shown in a few studies (146-148). Although not a direct assessment of hypoxia, contrast-enhanced ultrasonography could give additional perfusion/flow information which is related to the oxygenation status within the tumours. However, the availability of the microbubbles and the technical experience required have to be considered prior to its implementation.

**Conclusions**

Pathological evidence and to a lesser extent, invasive \( pO_2 \) assessment suggest that intratumoral hypoxia exists in a proportion of nasopharyngeal tumours, particularly in bulky primary and/or nodal disease. \([^{18}\text{F}]\text{FMISO}\) is the most widely studied imaging hypoxia biomarker, but its clinical use has been limited by its suboptimal pharmacokinetic properties. Newer generation nitroimidazoles and Cu-ATSM are viable alternatives although none of these tracers are without their limitations. Multimodality functional imaging with its potential to provide simultaneous information regarding perfusion, vessel permeability, tumour architecture and cellularity could herald a new paradigm in functional assessment of NPC.

**Acknowledgements**

This work was supported by financial support from the Department of Health via the National Institute of Health Research Biomedical Research Centre award to Guy's and St Thomas' NHS Foundation Trust in partnership with King’s College London and King’s College Hospital NHS Foundation Trust; the Comprehensive Cancer Imaging Centre funded by the Cancer Research UK and Engineering and Physical Sciences Research Council in association with the Medical Research Council and Department of Health, and the Singapore Ministry of Health’s National Medical Research Council under its NMRC Research Training Fellowship (Connie Yip).

**Footnote**

Conflicts of Interest: The authors have no conflicts of interest to declare.
References


Cite this article as: Yip C, Cook GJ, Wee J, Fong KW, Tan T, Goh V. Clinical significance of hypoxia in nasopharyngeal carcinoma with a focus on existing and novel hypoxia molecular imaging. Chin Clin Oncol 2016;5(2):24. doi: 10.21037/cco.2016.03.16